2017 News | Events | Industry Updates

08 December 2017
Selcia’s Fragment Library successfully used to generate hits for GPCR target using TR-FRET kinetic profiling method
18 September 2017
Selcia Discovery scientists continue to support Cypralis with integrated drug discovery services on their third successful Innovate UK award to identify novel inhibitors for fibrosis

Carol Austin, Associate Director of Discovery, who currently manages two Cypralis Innovate UK projects, said ‘Selcia’s unique expertise in the area of peptidyl prolyl isomerase assay development and screening should enable Cypralis to achieve the milestones for this third challenging project. We look forward to continuing to support Cypralis in achieving the goals of this new Innovate UK Feasibility award’.

Cypralis issued a press release on 18th September 2017; follow this link for the full version:

16 March 2017
Selcia awarded funding by MedCity to collaborate with Queen Mary University under their ‘Collaborate to Innovate’ scheme
01 March 2017
Selcia Discovery scientists to support Cypralis on Alzheimer’s disease project.
10 February 2017
Selcia, Cypralis and Gilead publish synthetic macrocyclic cyclophilin inhibitors inspired by natural product sanglifehrin A

Selcia, with colleagues from Cypralis and Gilead Sciences Inc., have published in the Journal of Medicinal Chemistry a novel strategy of structural simplification of a natural product to generate synthetically tractable cyclophilin inhibitors for the treatment of HCV. 

Pages